Eli Lilly and Company (NYSE:LLY), a United States-based pharmaceutical company, announced on Friday the retirement of Philip Johnson from the position of group vice president and treasurer.
Johnson is retiring from the company at the end of February to pursue a new professional opportunity. The successor to Johnson will be revealed at a future date.
Johnson headed the company's investor relations group for 11 years and was consistently named Top Investor Relations Officer by Institutional Investor. He worked as the company's treasurer since 2018 and has headed the firm's efforts within the financial community to drive positive social and economic change for underrepresented groups.
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business
Insmed receives highest ranking in Science's 2024 Top Employers Survey
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
Viatris added to Forbes' World's Best Employers 2024 list
Rarity Health named finalist for 21st MM+M Rare Disease Agency of the Year
AxoSim names new vice president of Sales and Marketing
Kyverna Therapeutics names new CEO and board member
Anervea.ai names new chief commercial officer and board member